Navigation Links
Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
Date:8/25/2008

COMPANY PRESENTS AT THOMAS WEISEL WEDNESDAY, SEPTEMBER 3RD AND NEWSMAKERS

IN THE BIOTECH INDUSTRY CONFERENCE THURSDAY, SEPTEMBER 4TH

SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer will be presenting at both the Thomas Weisel Healthcare Conference in Boston and the NewsMakers in the Biotech Industry Conference in New York.

The presentation at the Thomas Weisel Conference in Boston at the Four Seasons takes place Wednesday, September 3, 2008 at 2:05 p.m. Eastern Time (ET) / 11:05 a.m. Pacific Time (PT). The live presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

The presentation at the NewsMakers in the Biotech Industry Conference in New York at the Millennium Broadway will take place Thursday, September 4, 2008 at 10:00 a.m. Eastern Time (ET) / 7:00 a.m. Pacific Time (PT). The live presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend these webcasts and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentations to download or install any necessary software. A replay of both presentations will be available approximately one hour after the conclusion of the live event and will be archived on the Company's website for two weeks.

About Neurocrine

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences Reports Second Quarter 2008 Results
2. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
3. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
6. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
7. Neurocrine Announces Work Force Restructuring
8. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
9. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):